Online Event
Developing a biosimilar drug requires screening many samples originating from different cell lines to select the most appropriate ones for further process development. Each sample needs to be characterized by their critical q uality attributes, such as glycosylation or charge variants, which can be used to identify potentially harmful modifications in the samples. Common techniques used to determine the charge variants of a sample, such as ion exchange chromatography, are time- and material-consuming and